Kashif Q - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2015	1
2016	1
2017	1
2018	1
2025	0

Page 1

First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.

Talks JS, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N, McKibbin M, Bailey C, Mahmood S; United Kingdom Aflibercept Users Group. Talks JS, et al. Ophthalmology. 2016 Feb;123(2):337-343. doi: 10.1016/j.ophtha.2015.09.039. Epub 2015 Nov 12. Ophthalmology. 2016. PMID: 26578446 Clinical Trial.

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes.

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group. Chatziralli I, et al. Eye (Lond). 2018 Sep;32(9):1523-1529. doi: 10.1038/s41433-018-0114-3. Epub 2018 Jun 4. Eye (Lond). 2018. PMID: 29867156 Free PMC article.

Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration.

Talks JS, James P, Sivaprasad S, Johnston RL, McKibbin M; UK Aflibercept Users Group. Talks JS, et al. Eye (Lond). 2017 Nov;31(11):1613-1620. doi: 10.1038/eye.2017.86. Epub 2017 Jun 23. Eye (Lond). 2017. PMID: 28643799 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year